I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

William A. Hagstrom net worth and biography

William Hagstrom Biography and Net Worth

Director of CareDx

William Hagstrom has served as a member of our board of directors since March 2015. He is currently the founder and CEO of Octave Bioscience, an early stage molecular diagnostics company focused on neurodegenerative diseases and conditions. In 2007, Mr. Hagstrom secured financing for Crescendo Bioscience, a specialty diagnostics company focused on autoimmune and inflammatory diseases managed by rheumatologists. Serving as president and chief executive officer, he led the development of the company’s product pipeline, operations infrastructure and commercial strategy. In 2014, Crescendo was acquired by Myriad Genetics as a wholly owned subsidiary. Prior to founding Crescendo Bioscience, Mr. Hagstrom was president of Alpha BioPartners, a strategic consulting firm for early stage biotechnology companies. While at Alpha, Mr. Hagstrom co-founded Biolytx Pharmaceuticals and Altheus Therapuetics. Mr. Hagstrom also served as interim CEO of Selexys Pharmaceuticals and Inoveon. Previous to this he was Chairman and CEO of UroCor, a specialty diagnostics company focused on urological cancers and complex diseases. Under Mr. Hagstrom’s leadership, the company was an Inc. 500 company from 1992, 1993, 1994 and 1995, before becoming public in 1996. Previously, Mr. Hagstrom held executive positions at some of the largest multinational healthcare companies in the world, including Becton Dickinson, American Hospital Supply and Baxter International, where he served as vice president of the company’s billion-dollar scientific products division. Mr. Hagstrom has served on a variety of Boards over the last 15 years, including Prometheus Laboratories. Mr. Hagstrom received a BS degree in business management from Bob Jones University.

What is William A. Hagstrom's net worth?: The estimated net worth of William A. Hagstrom is at least $485,880.75 as of June 9th, 2021. Mr. Hagstrom owns 23,575 shares of CareDx stock worth more than $485,881 as of December 22nd. This net worth approximation does not reflect any other assets that Mr. Hagstrom may own. Learn More about William A. Hagstrom's net worth.
How do I contact William A. Hagstrom?: The corporate mailing address for Mr. Hagstrom and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected]. Learn More on William A. Hagstrom's contact information.
Has William A. Hagstrom been buying or selling shares of CareDx?: William A. Hagstrom has not been actively trading shares of CareDx during the past quarter. Most recently, William A. Hagstrom sold 5,000 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $88.14, for a transaction totalling $440,700.00. Following the completion of the sale, the director now directly owns 23,575 shares of the company's stock, valued at $2,077,900.50. Learn More on William A. Hagstrom's trading history.
Who are CareDx's active insiders?: CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.
Are insiders buying or selling shares of CareDx?: In the last twelve months, insiders at the sold shares 4 times. They sold a total of 96,340 shares worth more than $3,150,415.19. The most recent insider tranaction occured on November, 26th when Director Peter Maag sold 5,000 shares worth more than $125,000.00. Insiders at CareDx own 4.9% of the company. Learn More about insider trades at CareDx.
Information on this page was last updated on 11/26/2024.

William A. Hagstrom Insider Trading History at CareDx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2021	Sell	5,000	$88.14	$440,700.00	23,575
5/14/2021	Sell	10,000	$66.89	$668,900.00	23,320
5/6/2020	Sell	15,000	$29.12	$436,800.00	30,385
12/3/2019	Sell	12,500	$21.21	$265,125.00
6/4/2019	Sell	15,000	$32.35	$485,250.00	25,272

William A. Hagstrom Buying and Selling Activity at CareDx

CareDx Company Overview

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Today's Range

Now: $20.61

$20.10

$21.15

50 Day Range

MA: $23.54

$20.40

$31.31

2 Week Range

Now: $20.61

$7.42

$34.84

Volume

1,790,619 shs

Average Volume

887,120 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84

I was wrong. Dead wrong.

From Porter & Company | Ad